March 29, 2019
Mayo Clinic in the News Weekly Highlights for March 29, 2019
Reuters, Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value by Julie Steenhuysen — Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer’s disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, […]
Tags: AliveCor, alzheimer's disease, anal cancer, artificial Intelligence, Biogen, blood donation, Blood Donor Program, caffeine, cognitive decline, dementia, depression, Derrick Rose
version 3.3.6.2.8.1
Page loaded in 0.056 seconds